Ocugen shareholders are being asked to look a long way down the road. The company’s pivotal Phase 3 trial of OCU400 in retinitis pigmentosa, known as liMeliGhT, will not yield topline results until the first quarter of 2027 β more than a full year of waiting during which no efficacy readout will arrive to steady the stock. For a sector that reacts to weekly swings, that is a punishing stretch of silence.
The financing side of that wait is now front and center. Ocugen intends to expand its authorized common stock by 250,000,000 shares, a move that inevitably raises the dilution specter and highlights the delicate balance between securing liquidity and keeping existing holders onside. Late-stage clinical work is expensive, and with no operating cash flow to speak of, the equity market remains the default funding channel.
A MENA Licensing Deal, and What It Does Not Cover
To offset some of that development risk, Ocugen has leaned on regional alliances. Under its licensing agreement with Roots Pharmaceutical Company WLL and partner Al-Dhow International Holding for OCU400 across the Middle East and North Africa, the company has secured an upfront payment plus potential development milestones of up to $4 million. Commercial success would bring sales milestones of up to $255 million and a 22% royalty on net sales, with Ocugen also handling manufacturing and supply of the gene therapy.
Those terms offer useful validation and trim costs at the margin. What they cannot do is substitute for a commercial launch in the large Western core markets, which is where the real revenue case ultimately rests.
Insider Sales Add to the Chill
Sentiment has taken a further knock from activity at the top. Roughly a week ago, CEO Shankar Musunuri sold 468,727 directly held shares, while KVM Holdings, LLC disposed of 57,264 shares at an average price of $0.95 β both under a Rule 10b5-1 trading plan set up on June 5, 2026. Investors tend to take a dim view of management sales during sensitive periods, even when they are automated.
Should investors sell immediately? Or is it worth buying Ocugen?
Organizational groundwork continues in parallel. About two weeks ago, Jolanda Crombach took charge of the European subsidiary in Amsterdam, tasked with coordinating clinical development and eventual marketing across Europe. Ocugen also filed an investor presentation with the SEC outlining the next steps for its ophthalmology pipeline.
The Market’s Verdict So Far
The stock closed at EUR 0.7110 on Friday, leaving it down 43% since the start of the year and valuing the company at EUR 294.54 million. The market is demanding hard evidence of the pipeline’s future worth, and it is not yet getting it. On paper, the target indications carry substantial medical potential; in practice, the path to the finish line is paved with financial hurdles.
For anyone staying in or stepping aboard, the wager is less about the science than about whether management can steer the company to 2027 without intolerable dilution. Until the first Phase 3 data land, the shares remain a holding for investors with strong nerves.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from October 17 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 17.
Ocugen: Buy or sell? Read more here...
